NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that class action lawsuits can be filed on behalf of BioLineRx Ltd. shareholders. BLRXEnovix Corporation ENVXSouthwest Airlines Co. LUVand Y-mAbs Therapeutics, Inc. YMAB. Shareholders have until the deadlines below to petition the court to appear as lead plaintiffs. For more information on each case, see the link provided.

BioLineRx Ltd. BLRX

Class Period: February 23, 2021 – September 19, 2022

Lead Plaintiff Deadline: March 6, 2023

According to the Complaint, during the Class Period, Defendants made, among other things, false and/or misleading statements and/or failed to disclose that: (1) the Company was not adequately funded to develop Motixafortide while pursuing other pipeline programs; (2) BioLine would require a loan from Kreos Capital VII Aggregator SCSP in aggregate principal amount of up to US$40 million and then also a US$15 million securities offering to facilitate the commercial launch of Motixafortide; and (3) as a result of the foregoing, statements made by defendants about their businesses, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

When the truth came out, the lawsuit alleges that investors suffered harm.

For more information on the BioLineRx class action go to: https://bespc.com/cases/BLRX

Enovix Corporation ENVX

Class period: February 22, 2021 – January 3, 2023

Lead Plaintiff Deadline: March 7, 2023

Enovix claims to design, develop and manufacture silicon anode lithium-ion batteries using a proprietary 3D cell architecture, which the company says allows its batteries to achieve higher energy densities. Enovix hopes to be able to customize and supply its batteries to other companies who can then integrate them into their consumer electronics, such as: B. wearable smartwatches, VR headsets, laptops, mobile phones…